JAZZ Logo

Jazz Pharmaceuticals plc (JAZZ) 

NASDAQ
Market Cap
$6.89B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
93 of 776
Rank in Industry
67 of 433

Largest Insider Buys in Sector

JAZZ Stock Price History Chart

JAZZ Stock Performance

About Jazz Pharmaceuticals plc

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in …

Insider Activity of Jazz Pharmaceuticals plc

Over the last 12 months, insiders at Jazz Pharmaceuticals plc have bought $1.44M and sold $1.37M worth of Jazz Pharmaceuticals plc stock.

On average, over the past 5 years, insiders at Jazz Pharmaceuticals plc have bought $3.49M and sold $10.53M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Johnson Philip L (EVP & Chief Financial Officer) — $1.44M.

The last purchase of 12,000 shares for transaction amount of $1.44M was made by Johnson Philip L (EVP & Chief Financial Officer) on 2024‑03‑01.

List of Insider Buy and Sell Transactions, Jazz Pharmaceuticals plc

2024-11-01SaleChairman & CEO
1,000
0.0016%
$110.84$110,840-0.94%
2024-09-06SaleSVP, Technical Operations
1,410
0.0023%
$108.30$152,703+2.33%
2024-06-07SaleSVP, Chief Accounting Officer
163
0.0003%
$108.83$17,738-1.29%
2024-05-03SaleEVP & Chief Legal Officer
5,000
0.008%
$109.65$548,250-0.28%
2024-03-07SaleSVP, Chief Accounting Officer
1,768
0.0028%
$116.98$206,821-4.84%
2024-03-06SaleSVP, Chief Accounting Officer
1,936
0.0032%
$119.64$231,628-5.53%
2024-03-01PurchaseEVP & Chief Financial Officer
12,000
0.0192%
$119.65$1.44M-6.64%
2023-12-04Saledirector
417
0.0007%
$119.27$49,736-6.04%
2023-12-04Saledirector
417
0.0007%
$119.27$49,736-6.04%
2023-09-01SaleEVP & Chief Legal Officer
1,500
0.0024%
$144.25$216,375-16.30%
2023-08-29SaleSVP, Chief Accounting Officer
142
0.0002%
$143.47$20,373-16.22%
2023-08-15SaleEVP & Chief Legal Officer
750
0.0012%
$139.59$104,695-13.50%
2023-08-14Saledirector
1,241
0.0019%
$138.16$171,455-13.48%
2023-08-14Saledirector
1,241
0.0019%
$138.16$171,455-13.48%
2023-08-14Saledirector
1,344
0.0021%
$138.16$185,685-13.48%
2023-08-14Saledirector
1,241
0.0019%
$138.16$171,455-13.48%
2023-08-14Saledirector
1,241
0.0019%
$138.16$171,455-13.48%
2023-08-14Saledirector
1,241
0.0019%
$138.16$171,454-13.48%
2023-08-14Saledirector
1,241
0.0019%
$138.16$171,454-13.48%
2023-08-14Saledirector
1,241
0.0019%
$138.16$171,455-13.48%

Insider Historical Profitability

<0.0001%
COZADD BRUCE CChairman & CEO
428976
0.6947%
$111.571101+194.39%
Johnson Philip LEVP & Chief Financial Officer
27932
0.0452%
$111.5710
MICHELSON MICHAEL Wdirector
9906501
16.042%
$111.5710<0.0001%
RAETHER PAUL E
9906501
16.042%
$111.5710<0.0001%
KKR JP LLC
9906501
16.042%
$111.5710<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
BlackRock$851.36M11.217.07M+0.2%+$1.67M0.02
The Vanguard Group$776.55M10.236.45M+1.33%+$10.23M0.01
State Street$296.49M3.92.46M+1.69%+$4.94M0.01
LSV Asset Management$286.7M3.782.38M+1.61%+$4.53M0.6
JPMorgan Chase$179.97M2.371.49M+6.96%+$11.71M0.02
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.